GEN News Highlights

Merck Serono to Use Biolex’ Technology for Antibody Optimization

(Page
1
of
1)

Merck Serono plans to use Biolex Therapeutics’ LEX System to evaluate antibody optimization and production. Merck Serono will investigate whether this platform has the ability to improve therapeutic profiles of its antibody candidate through optimization of antibody glycosylation structures.

Biolex engineered the LEX System to produce antibodies with a fully human glycosylation structure without fucose. The technology also has the ability to produce antibodies that have a fully G0 glycosylation structure, lacking galactose, the company adds. These two innovations reportedly produce antibodies with greater efficacy and potency, less side effects, and reduced infusion times.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.